The purpose of the IBC is to ensure that the NIH Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules are adhered to at FIU. The purpose of the NIH Guidelines is to specify the practices for constructing and handling: (i) recombinant nucleic acid molecules, (ii) synthetic nucleic acid molecules, including those that are chemically or otherwise modified but can base pair with naturally occurring nucleic acid molecules, and (iii) cells, organisms, and viruses containing such molecules. See the section Definition of Recombinant or Synthetic Nucleic Acid Molecules for further detail. Additional guidance can be found here.
FIU requires that all research and teaching activities involving recombinant and/or synthetic nucleic acid molecules at the University be registered and approved with the Institutional Biosafety Committee prior to commencing any activities (regardless if the study falls under Section III-E or III-F of the NIH Guidelines). Therefore, studies falling under Section III-E require IBC approval prior to commencing with the activities. Studies falling under Section III-F require an IBC exemption approval prior to commencing with the activities.
This site contains the necessary tools and information to assist investigators during the IBC protocol submission and review process. You can find them on the left navigation menu including Obtaining IBC Approval which provides guidance on whether your work would fall under the IBC purview, as well as, step by step instructions on preparing your submission, Policies & Procedures which contains helpful resources on conducting research with Recombinant or Synthetic Nucleic Acid, and IBC FAQs which contains answers to commonly asked questions.
The Office of Research Integrity (ORI) is responsible for the ethical and regulatory oversight of research at Florida International University that involves Recombinant or Synthetic Nucleic Acid Molecules. ORI supports and oversees the work of the Institutional Biosafety Committee (IBC).
The IBC Chairperson is Kathleen Rein and can be reached at: (305) 348-6682.